[Malignant lymphoma with c-myc gene rearrangement in a patient receiving long-term treatment for multiple myeloma].
We encountered a 65-year-old woman with diffuse large B-cell lymphoma showing t(8;14)(q24;q32) and c-myc gene rearrangement that developed following 12 years of melphalan-based chemotherapy for multiple myeloma. Short-term remission was obtained by CHOP chemotherapy. However, shortly thereafter the patient died of an aggressive progression of lymphoma. It was suspected that the lymphoma was a secondary malignancy related to the treatment with cytotoxic agents and radiation for prolonged multiple myeloma. The chromosomal abnormality t(8;14)(q24;q32) is rare in secondary malignancies. Overexpression of c-myc by gene rearrangement may be associated with clinical courses manifested by the rapid progression of lymphoma.
Ohnishi
H
H
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka.
Kamimura
T
T
Gondo
H
H
Okamura
T
T
Niho
Y
Y
Yao
T
T
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D002883:Chromosomes, Human, Pair 14; D002898:Chromosomes, Human, Pair 8; D017809:Fatal Outcome; D005260:Female; D015321:Gene Rearrangement; D016259:Genes, myc / Q000235:genetics*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000139:chemically induced / Q000235:genetics*; D008558:Melphalan / Q000009:adverse effects; D009101:Multiple Myeloma / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics*; D014178:Translocation, Genetic
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan